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The anthracycline antibiotics, DOX and DAUN, are commonly-used, effective treatments for solid tumors and acute myeloid leukemias (Weiss, 1992) . Unfortunately, the widespread use of the anthracyclines is limited by the development of dose-dependent chronic cardiotoxicity in patients. This side effect manifests as an irreversible disorder following long-term treatment with approximately 20% of cases leading to congestive heart failure (Singal and Iliskovic, 1998) .
Though the mechanism by which this side effect develops is not yet identified, evidence implicates metabolism as an important factor (Olson and Mushlin, 1990) . Following DOX or DAUN administration, the C-13 alcohol metabolites, DOXol and DAUNol, are the major identified metabolites (Takanashi and Bachur, 1976) , and these metabolites are speculated to be responsible for causing cardiac tissue damage (Del Tacca et al., 1985; Boucek et al., 1987; Cusack et al., 1993; Behnia and Boroujerdi, 1999; Olson et al., 2003; Sacco et al., 2003) .
Formation of DOXol and DAUNol is mediated by cytosolic oxidoreductase enzymes of the AKR and short-chain dehydrogenase/reductase families, with the AKR1A1, AKR1B10, AKR1C2, and carbonyl reductase enzymes identified as major catalysts (Licata et al., 2000; Martin et al., 2006; Jin and Penning, 2007; Oppermann, 2007) . Inhibition of the anthracyclinemetabolizing enzymes is suggested as a strategy for avoiding treatment-related cardiotoxicity (Behnia and Boroujerdi, 1999) and chemical inhibitors for reductases and anthracycline derivatives that are metabolically less labile have been explored for their potential roles as safer alternatives to the currently-used anthracycline drug treatments. In part, the success of these strategies relies on accurately identifying the enzymes responsible for anthracycline metabolism.
In this paper, we characterize the involvement of two recombinant aldo-keto reductase enzymes, AKR1A1 and AKR1C2, in mediating the in vitro production of DAUNol and DOXol from DAUN and DOX using a specific and sensitive HPLC-fluorescence assay for direct measurement of the alcohol metabolites.
This article has not been copyedited and formatted. The final version may differ from this version. Cloning of human AKR1A1 and 1C2. The AKR1A1 and AKR1C2 genes were subcloned from lab vector constructs (p2ZOp2N-AKR1A1 and p2ZOp2N-AKR1C2) using standard molecular cloning techniques to the prokaryotic expression vector pET28a (Novagen, Madison, WI) as previously described (Bains, O.S.B. et al., 2008) . The expression constructs encoded an AKR with a six-histidine affinity tag separated by a 23-amino acid residue linker attached to the amino terminus of the expressed protein.
Expression of recombinant enzymes. The AKR proteins were expressed and purified from Escherichia coli cultures. Briefly, pET28a-AKR constructs were transformed by heat-shock into BL21 (DE3) pLysS and grown in 500 ml low-salt LB media supplemented with 50 µg/ml kanamycin sulfate and 25 µg/ml chloramphenicol at 37ºC. Expression was induced by addition of isopropyl β -D-1-thiogalactopyranoside administration to a final concentration of 1 mM and the cultures grown for a further 3 hours. Bacterial pellets were collected by centrifugation (4000 rpm for 20 mins at 4ºC), then resuspended at 5 ml per gram wet weight with 300 mM NaCl, 50 mM The recombinant proteins were detected by Western blot analysis using the Odyssey Infrared
Imaging System (LI-COR ® Biosciences, Lincoln, NE) with the primary monoclonal AKR1A1
and AKR1C2 antibodies (Abnova Corporation, Taipei City, Taiwan) diluted 1:5000 and 1:3000, respectively, and secondary IRDye 800CW goat anti-mouse IgG antibody (LI-COR ® Biosciences), diluted 1:5000. Protein concentrations were determined by the Bradford method using bovine serum albumin as a standard (BioRad, Hercules, CA). Protein purity was assessed by SDS-PAGE stained with Sypro Ruby (Invitrogen, Burlington, ON).
Measurement of AKR enzyme activities. AKR activity was measured by monitoring the initial rate of NADP(H) oxidation/reduction reactions using standard conditions (Penning, 2004) . DOXol equivalents using a response ratio of 1.0. The limit of quantification for DOXol was estimated as 25 nM. All data processes were performed with Waters Empower software (ver 2.0).
Purified tagged AKR1A1 and AKR1C2 proteins were incubated in 150 µl reaction mixtures containing 25 mM KH 2 PO 4 , pH 7.4; and 1 µM of DOX or DAUN at 37ºC. Reaction conditions were selected to reflect a human physiological environment. Reactions were initiated with the addition of 1 mM NADPH. Incubations were conducted with up to 1 µg of purified protein for 120 and 240 minutes for DAUN and DOX, respectively, to maximize metabolite generation given the apparent low activity of these enzymes. At the end of the incubations, reductase activity was stopped with the addition of 150 µl of ice-cold acetonitrile that contained idarubicin as an internal standard. Protein was removed from the sample by vortex mixing and centrifugation at 10,000×g for 10 minutes at 4ºC, and the supernatant was removed for HPLC analysis. All incubations were conducted in triplicate for each purified protein preparation.
RESULTS AND DISCUSSION
The expression of the recombinant tagged AKR1A1 and AKR1C2 was confirmed by Western blot analysis showing bands with mobility corresponding to the molecular weight of the tagged AKRs (~41-42 kDa) (Figure 1 ). Total protein staining of a SDS-PAGE gel demonstrated that the only detectable bands for the purified preparations corresponded to the AKR1A1 and AKR1C2
proteins identified by Western blotting (Figure 1 ). The high substrate specificity of AKR1A1 was also demonstrated in our results from recombinant enzymes where DAUN was metabolized to a much greater extent than DOX. The levels of DOXol generated were too low for quantification using the HPLC assay, whereas specific reductase activities of 1.71±0.09 pmol/min/mg were determined for DAUN reduction.
Our findings of a lack of AKR1C2 involvement in DOX and DAUN metabolism differ from previously published results (Ohara et al., 1995) . This discrepancy may be due to contaminating proteins in previous enzyme preparations or non-specific measurement of reductase activities.
SDS-PAGE gel staining for our enzyme preparations shows absence of any detectable contaminating proteins following affinity chromatography. Sypro Ruby total protein staining This article has not been copyedited and formatted. The final version may differ from this version. HPLC-fluorescence assay and do not identify any alcohol metabolites formed by AKR1C2 that exceed the limit of quantification of the assay (25 nM). In our in vitro system, the initial anthracycline concentrations are 1 µM, a physiologically-relevant concentration for patient cardiac tissue (Stewart et al., 1993) .
The failure of AKR1C2 to generate alcohol metabolites in vitro suggests that it is unimportant for the generation of DOX or DAUN metabolites in vivo. We recognize that in vivo studies are needed to clearly define the role of AKR1C2 in anthracycline metabolism; however, the conduct of definitive studies will be difficult. Several reductase enzymes are involved in the metabolism of these drugs and distinguishing their individual contributions to the total metabolism will be a challenge using the traditional approaches of correlation studies and chemical or antibody inhibition. It is with these considerations that we present our in vitro findings to focus future work on anthracycline metabolism on the other AKR isoforms and carbonyl reductases.
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